EP1322778A4 - Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas - Google Patents

Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Info

Publication number
EP1322778A4
EP1322778A4 EP01977351A EP01977351A EP1322778A4 EP 1322778 A4 EP1322778 A4 EP 1322778A4 EP 01977351 A EP01977351 A EP 01977351A EP 01977351 A EP01977351 A EP 01977351A EP 1322778 A4 EP1322778 A4 EP 1322778A4
Authority
EP
European Patent Office
Prior art keywords
cyr61
diagnosis
treatment
human uterine
uterine leiomyomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01977351A
Other languages
German (de)
French (fr)
Other versions
EP1322778A2 (en
Inventor
Zhiming Zhang
Deepak Sampath
Yuan Zhu
Richard Winneker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1322778A2 publication Critical patent/EP1322778A2/en
Publication of EP1322778A4 publication Critical patent/EP1322778A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP01977351A 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas Withdrawn EP1322778A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23688700P 2000-09-29 2000-09-29
US236887P 2000-09-29
PCT/US2001/030783 WO2002026193A2 (en) 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Publications (2)

Publication Number Publication Date
EP1322778A2 EP1322778A2 (en) 2003-07-02
EP1322778A4 true EP1322778A4 (en) 2005-06-15

Family

ID=22891403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01977351A Withdrawn EP1322778A4 (en) 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Country Status (5)

Country Link
EP (1) EP1322778A4 (en)
JP (1) JP2004509909A (en)
AU (1) AU2001296477A1 (en)
CA (1) CA2423413A1 (en)
WO (1) WO2002026193A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858324B2 (en) * 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
EP2540742A4 (en) * 2009-12-04 2014-02-12 Shanghai Inst Of Immunology Anti-cyr61 protein monoclonal antibodies and uses thereof
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
CN108752454B (en) * 2018-06-19 2021-07-20 中山大学孙逸仙纪念医院 Human CYR61 protein Ser188 site phosphorylation antigen and antibody, and preparation method and application thereof
RU2704817C1 (en) * 2019-07-09 2019-10-31 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Method for predicting uterine leiomyoma size increase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
WO2002026193A2 (en) 2002-04-04
EP1322778A2 (en) 2003-07-02
WO2002026193A9 (en) 2003-02-20
CA2423413A1 (en) 2002-04-04
AU2001296477A1 (en) 2002-04-08
WO2002026193A3 (en) 2002-10-03
JP2004509909A (en) 2004-04-02

Similar Documents

Publication Publication Date Title
AU1166502A (en) Human ect2 and methods of use
HUP1500560A2 (en) Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
IL205242A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
AU3679801A (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
HK1049605A1 (en) Treatment of human herpesviruses using hyperthermia
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
EP1129217A4 (en) Compositions and methods of disease diagnosis and therapy
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
ID27576A (en) USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
GB0011052D0 (en) Medical device and use thereof
EP1161451A4 (en) Human endokine alpha and methods of use
IL151019A0 (en) Microcompetition and human disease
GB9908059D0 (en) Diagnosis and treatment of diseases
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
AU2001253024A1 (en) Diagnosis and treatment of gastrointestinal disease
AU2001233934A1 (en) Ccr2-64i, polymorphic variant of the human ccrs receptor and its use in the diagnostic and treatment of atherosclerosis
GB0029879D0 (en) Skin disease diagnosis and treatment
GB0029225D0 (en) Skin disease diagnosis and treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030331

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050428

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401